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OBJECTIVE — Cases of acute pancreatitis have been reported in association with exenatide,
sitagliptin, and type 2 diabetes without use of these medications. It remains unknown whether
exenatide or sitagliptin increase the risk of acute pancreatitis.
RESEARCH DESIGN AND METHODS — A retrospective cohort study of a large med-
icalandpharmacyclaimsdatabasewasperformed.Datafor786,656patientswereanalyzed.Cox
proportionalhazardmodelswerebuilttocomparetheriskofacutepancreatitisbetweendiabetic
and nondiabetic subjects and between exenatide, sitagliptin, and control diabetes medication
use.
RESULTS — Incidenceofacutepancreatitisinthenondiabeticcontrolgroup,diabeticcontrol
group, exenatide group, and sitagliptin group was 1.9, 5.6, 5.7, and 5.6 cases per 1,000 patient
years, respectively. The risk of acute pancreatitis was signiﬁcantly higher in the combined
diabetic groups than in the nondiabetic control group (adjusted hazard ratio 2.1 [95% CI
1.7–2.5]). Risk of acute pancreatitis was similar in the exenatide versus diabetic control group
(0.9 [0.6–1.5]) and sitagliptin versus diabetic control group (1.0 [0.7–1.3]).
CONCLUSIONS — Our study demonstrated increased incidence of acute pancreatitis in
diabeticversusnondiabeticpatientsbutdidnotﬁndanassociationbetweentheuseofexenatide
or sitagliptin and acute pancreatitis. The limitations of this observational claims-based analysis
cannot exclude the possibility of an increased risk.
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T
hemostrecentlyapprovedclassesof
agents for treatment of type 2 diabe-
tes are the glucagon-like peptide-1
(GLP-1) receptor agonists and dipeptidyl
peptidase-4 inhibitors. Postmarketing
surveillance of exenatide, the ﬁrst GLP-1
receptor agonist, and sitagliptin, the ﬁrst
dipeptidyl peptidase-4 inhibitors, has
raised the possibility of acute pancreatitis
in association with their use (1–4). Based
on case reports, the U.S. Food and Drug
Administration (FDA) has added warn-
ings about acute pancreatitis to the label-
ing information of exenatide and
sitagliptin (5,6). More recently, acute
pancreatitis has been reported to occur
more often in clinical trials of patients
who took liraglutide, a GLP-1 agonist ap-
proved by the FDA in January 2010 (7).
TheFDAisrequiringariskevaluationand
mitigation strategy to help patients and
health care providers understand the po-
tential risk of acute pancreatitis with
liraglutide.
As the use of incretin-based therapies
increases, it is critical that potential ad-
verse effects be fully characterized so cli-
nicians and patients can balance potential
beneﬁts and harms of these agents. Clin-
icaltrialsareunlikelytoprovidedeﬁnitive
answers about whether incretin-based
therapies increase acute pancreatitis be-
cause this condition occurs at a very low
frequency and because type 2 diabetes is
associated with increased incidence of
acute pancreatitis (8). Although epidemi-
ological analyses have numerous limita-
tions and cannot provide deﬁnitive
conclusions, they may be helpful in ex-
ploringrelationshipsbetweenmedication
use and very low frequency adverse
events. We performed an analysis of a
large medical and pharmacy claims da-
tabase to evaluate the relationship be-
tween exenatide, sitagliptin, and acute
pancreatitis.
RESEARCH DESIGN AND
METHODS— The source of data was
the Medco National Integrated Database,
which stores medical and pharmacy
claims data. Medco’s data repository con-
tains 36 months of pharmacy claims for
60 million lives. More than 450 insur-
ance plans provide medical claims data
for 13 million patients. Medical and
pharmacy data are linked by a Medco-
assignedidentiﬁcationnumber.Themed-
ical claims contain all inpatient,
outpatient, nursing home, and laboratory
and diagnostic testing claims the insur-
ance plan has received. Laboratory values
and medical care paid out of pocket or
through Medicare are not included in the
database.
Patientsaged18–63yearswithphar-
macy and medical claims data for a con-
tinuous period of at least 12 months
between 1 January 2007 and 30 June
2009 were included in this study. This
alloweda6-monthperiodforbaselineob-
servations and at least 6 months of obser-
vation after initiation of the index
medication. Patients 63 years were ex-
cluded from the analysis because of the
possibility of incomplete medical data
due to dual Medicare coverage.
Diabetic patients were identiﬁed by
the presence of at least one ICD-9 code of
250.XX during the study. The index date
was deﬁned as the ﬁll date of the ﬁrst
claim for a new antidiabetes drug during
the target period 1 July 2007 through 31
December 2008. An antidiabetes drug
was considered new if there were no
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6 months. Based on the new antidiabetes
drug (index drug), patients were divided
into three groups: 1) exenatide group
(new exenatide start); 2) sitagliptin group
(new sitagliptin start); and 3) diabetic
controlgroup(anewsulfonylurea,bigua-
nide,orthiazolidinedioneandnositaglip-
tin or exenatide prescription during the
entire study period).
Patients with acute pancreatitis 6
months before or on the index date were
excluded. Patients with other pancreatic
diseases, e.g., chronic pancreatitis, were
included. The following additional exclu-
sionsapplied:treatmentwithrepaglinide,
nateglinide, acarbose, or miglitol (n 
4,153)andtreatmentwithbothexenatide
and sitagliptin (n  6,399). Nondiabetic
patients were included as a second con-
trol group. Patients in the nondiabetic
control group had at least one prescrip-
tion claim for any medication other than
antidiabetes medications (exenatide, sita-
gliptin, metformin, sulfonylureas, thiazo-
lidinediones, insulin, acarbose, miglitol,
repaglinide, or nateglinide) during the
target period, at least one medical claim
during the wash-in period or target pe-
riod, and no ICD9 code of 250.XX or an-
tidiabetes medication during the entire
study period. The index date for the non-
diabetic control group was a randomly
generated date during the target period.
The observation period started on the
indexdateandendedattheoccurrenceof
one of the following events, whichever
was the earliest: 1) acute pancreatitis; 2)
30 days after the index drug supply was
predicted to run out (diabetic patients),
based on the supply of drug that was dis-
pensed; 3) 18 months of follow-up; or 4)
end of eligibility. A secondary analysis
was performed when exclusion 2 did not
apply.
Acute pancreatitis was determined by
aclaimforICD-9code577.0.Thefollow-
ing risk factors for acute pancreatitis were
determined from ICD-9 code claims data:
hypertriglyceridemia (272.1), alcoholism
(291.xx, 303.xx), biliary stone disease
(574.xx, 575.xx), cholestatic liver disease
(573.8), and pancreatic disease (577.1,
577.2, 577.8, 577.9, 157.xx). In addi-
tion, information on lipid-lowering
drugs, glucocorticoids, azathioprine,
mercaptopurine, sulfonamides, tetracy-
clines, nonsteroidal anti-inﬂammatory
agents, and -methyldopa was collected
becauseoftheircommonassociationwith
acute pancreatitis. Chronic disease score
was calculated from pharmacy claims
data by a method proposed by Von Korff
et al. (9).
Statistical analysis
The primary outcome was the ﬁrst occur-
rence of acute pancreatitis after the index
date. All data were summarized as
mean  SD or number and percentage.
The overall diabetic group (combined ex-
enatide, sitagliptin, and diabetic control)
was compared with the nondiabetic con-
trol group. Exenatide and sitagliptin
groups were compared separately with
the diabetic control group. Continuous
variables were compared using an un-
paired t test. Categorical variables were
comparedusingthe
2test.Kaplan-Meier
survival curves were constructed for each
group to show the time to acute pancre-
atitis. Cox proportional hazard models
were built to compare the adjusted risk of
acutepancreatitisindiabetic(versusnon-
diabetic control) patients and in patients
treated with exenatide and sitagliptin
(versus other antidiabetic medications).
Independent variables included age, sex,
hypertriglyceridemia, alcohol abuse, bili-
arystonedisease,cholestaticliverdisease,
and drug therapy. All analyses were per-
formed with SAS software (version 9.1).
RESULTS— Baseline characteristics
are shown in Table 1. Diabetic patients
were slightly older than nondiabetic pa-
tients. The exenatide group was slightly
younger and included more women than
the other diabetic groups. Chronic dis-
easescorewashigherintheexenatideand
sitagliptingroups.Boththeexenatideand
sitagliptin groups received more antidia-
betes drugs from multiple classes before
starting the index drug. Lipid-lowering
drugs were also used more often in the
exenatide and sitagliptin groups. Sulfon-
amides were used more often in the ex-
enatide group, whereas there were no
differences in use of other drugs associ-
ated with pancreatitis. Other acute pan-
creatitis risk factors were equally
distributed except that hypertriglyceride-
mia was more common in the exenatide
and sitagliptin groups. Incidence of acute
pancreatitis is also shown in Table 1.
Acute pancreatitis was more frequent in
the overall diabetic group compared with
that in the nondiabetic control group, but
therewerenodifferencesamongthethree
diabetic groups.
Figure 1 shows the Kaplan-Meier
curve of time to acute pancreatitis in pa-
tientswithdiabetescomparedwiththatin
nondiabetic control patients. In the Cox
proportional hazard model that con-
trolled for diabetes, age, preexisting pan-
creatic disease, alcohol intake, biliary
stone disease, and chronic disease score,
patients with diabetes were 2.1 times
more likely to have a claim for acute pan-
creatitis than patients without diabetes
(Table 2). Figure 2 shows the Kaplan-
Meier curve of time to acute pancreatitis
inthediabeticsubgroups.IntheCoxpro-
portional hazards model for the diabetic
subgroups,acutepancreatitiswasnotsig-
niﬁcantlyhigherintheexenatideandsita-
gliptin groups compared with that in the
diabeticcontrolgroup(Table3).Thesen-
sitivity analysis indicated that extending
follow-up beyond 30 days of running out
of the index medication did not signiﬁ-
cantly affect the results.
CONCLUSIONS — This study con-
ﬁrms prior ﬁndings that the incidence of
acute pancreatitis is approximately two
times higher in patients with type 2 dia-
betes. However, we did not ﬁnd an in-
creased risk for acute pancreatitis with
exenatide or sitagliptin.
Our negative ﬁndings are consistent
with those of Dore et al. (10). However,
these studies need to be interpreted with
cautioninviewoftheinherentlimitations
with retrospective observational insur-
ance and pharmacy claims–based studies
that may have incomplete data and un-
knownconfounders.ThestudyofDoreet
al., funded by Amylin Pharmaceuticals,
analyzed an insurance claims database to
investigatetheriskofacutepancreatitisin
patients treated with exenatide and sita-
gliptin compared with that in patients
taking metformin or glyburide. The inci-
dence of acute pancreatitis was extremely
low with exenatide (0.13%) and sitaglip-
tin (0.12%), and the risk of acute pancre-
atitis was comparable for patients
initiating exenatide or sitagliptin com-
pared with glyburide and metformin.
Dore et al. used propensity scoring meth-
odology, excluded patients with evidence
of pancreatic disease and did not adjust
for known pancreatitis risk factors. In
contrast,ourstudyincludedpatientswith
evidence of chronic pancreatic disease
and estimated risk of acute pancreatitis
using Cox models adjusted for numerous
medicalconditionsandmedicationsasso-
ciatedwithanincreasedriskofacutepan-
creatitis. Our study identiﬁed a total of
154 cases of acute pancreatitis whereas
their study identiﬁed 92 cases, which
gave our study greater power to detect
potential effects of these medications.
Pancreatitis with exenatide and sitagliptin
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our diabetic cohort (5.63 cases per 1,000
patientyears)issimilartothatreportedin
a claims analysis reported by Noel et al.
(8) (4.22 cases per 1,000 patient years).
They reported a similar increased risk for
acute pancreatitis (adjusted hazard ratio
[HR] of 2.8), which was very similar to
that in our study (adjusted HR of 2.1). In
contrast, Girman et al. (11) recently re-
portedalowerriskofacutepancreatitisin
patients with type 2 diabetes (adjusted
HR of 1.49). Because their analysis was
performed using the U.K. General Prac-
tice Research Database, which contains
clinical as well as claims data, they were
able to adjust for data, such as incidence
of obesity, that are probably underre-
ported using claims data.
Our claims data analysis had the
strengthofallowingobservationofalarge
number of patients treated with these
drugs throughout the country. The data
therefore have good generalizability to
other insured populations across geo-
graphic regions. The differences in base-
line characteristics are representative of
the trends expected in clinical practice.
Thus, diabetic patients were older than
nondiabetic patients, were taking more
medications, and had a higher chronic
diseasescore.Bothexenatideandsitaglip-
tin group patients were taking multiple
antidiabetes drugs as well as more lipid-
lowering drugs and had higher chronic
disease scores compared with those for
the diabetic control group. These obser-
vations suggest that exenatide and sita-
gliptin may have been used later in the
course of disease and in sicker patients.
Exenatide, an injectable drug, was used
more often in younger patients and in
women. Exenatide is associated with
weight loss and may be preferentially se-
lected in obese patients for this reason.
However,despitethispotentialindication
bias,wedidnotﬁndahigherincidenceof
acute pancreatitis in association with
these drugs.
The study has numerous important
limitations,andtheresultsshouldbecon-
sidered with these in mind. Most impor-
tant, the nonrandom nature of the study
may have introduced unmeasured con-
founders. For example, if prescribers
were aware of the possible risks of pan-
creatitis associated with incretin-based
therapy,theymayhavepreferentiallypre-
scribed other antidiabetic medications to
patients perceived to be at higher risk.
This channeling bias could have inﬂated
the risk of acute pancreatitis in diabetic
patients taking control medications,
masking a potential real increased risk
with exenatide and sitagliptin. We at-
temptedtominimizetheeffectofthisbias
by measuring and adjusting for risk fac-
tors for acute pancreatitis. However, our
ability to detect patients at increased risk
was limited to conditions detectable by
medical and pharmacy claims. Our ad-
ministrative claims dataset did not pro-
vide potentially relevant demographic
and clinical details such as type and du-
ration of diabetes, obesity, glycemic and
lipid control, alcohol consumption, and
acute pancreatitis that occurred before
the baseline period. Although we ad-
Table 2—Cox proportional hazards analysis for time to pancreatitis for diabetic and nondi-
abetic patients
(Adjusted age
and sex)
HR (95% CI) P value
(Adjusted all)
HR (95% CI) P value
Diabetic patients 2.9 (2.5–3.5) 0.0001 2.1 (1.7–2.5) 0.0001
Age 1.0 (1.0–1.0) NS 0.99 (0.98–0.99) 0.005
Sex (female  1) 1.2 (1.1–1.3) 0.001 1.1 (1.0–1.2) NS
Medical history
Pancreatic disease 24.7 (18.4–33.3) 0.0001
Alcohol abuse 6.2 (4.5–8.6) 0.0001
Biliary stone disease 2.6 (1.9–3.5) 0.0001
Hypertriglyceridemia 1.4 (0.9–2.0) NS
Cholestatic liver disease 1.4 (0.9–2.3) NS
CDS 1.021 (1.018–1.023) 0.0001
Figure 1—Kaplan-Meier curve of acute pancreatitis in combined diabetic groups (exenatide, sitagliptin, diabetes control) and the nondiabetic
control group.
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demia, obesity, and alcohol abuse
identiﬁed by medical claims, claims of
these types are probably undercoded and
inconsistently coded.
Data capture for patients included
may not have been complete if there were
secondary insurance policies that were
not administered through Medco or if the
patientspaidfortheirmedicalcostsoutof
pocket. There were likely to have been
coding inaccuracies, which are an inher-
entlimitationofclaimsdata.Importantto
this analysis, the incidence of pancreatitis
in this population may be overestimated
because providers may have used the
acute pancreatitis code when evaluating
patients for “rule-out” pancreatitis. How-
ever, it is likely that these inaccuracies
would affect the diabetic treatment group
patientsequally.Patients63yearsofage
were excluded because of incomplete
data.Ouranalysesdidnotincludeadjust-
ment for medication dose or adherence,
and we were not able to conﬁrm that pa-
tients were actually taking medications
for which claims were ﬁled. We were also
unable to investigate the interaction be-
tween exenatide and sitagliptin and risk
factors for acute pancreatitis because of
small numbers. The possibility of asymp-
tomatic chronic pancreatitis and the po-
tential for pancreatic carcinoma with
long-term use, as suggested by some ex-
perts (12), was not investigated in this
study. A few animal studies have shown
incretinomimetic drugs to cause exocrine
pancreatic duct hyperplasia that may
eventually lead to acute or chronic pan-
creatitis or pancreatic carcinoma (13,14).
Despite these limitations, these data
provide valuable information for practic-
ingcliniciansweighingpotentialreported
beneﬁts versus risks, including the FDA
warning of increased pancreatitis. Al-
though this retrospective analysis cannot
rule out with certainty that an association
between exenatide, sitagliptin, and acute
pancreatitis exists, it appears that ex-
enatide and sitagliptin may not be associ-
ated with a large increased risk of acute
pancreatitis.
Treatment with the incretin-based
therapies appears to be increasing, and
there are several new agents that have
come to market or may come soon. These
agents are attractive in that they may al-
low treatment intensiﬁcation while body
weight is controlled through mechanisms
associated with a low rate of hypoglyce-
mia. Our ﬁndings did not reveal any in-
creased risk of acute pancreatitis with
exenatide and sitagliptin, but this retro-
spective study cannot rule out with cer-
taintytheexistenceofsuchanassociation.
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